Recent 8-K filings for OFIX

• May 21, 2026, 8:00 AM ET regulatory materiality 0.80 negative item 7.01

  Orthofix cuts FY2026 guidance as CMS cuts bone stimulator reimbursement ~10%

  CMS reduced Medicare reimbursement for HCPCS codes E0747, E0748, E0760 by ~10% effective May 18, 2026.

• May 5, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Orthofix Q1 pro forma revenue $196.4M +2.7% constant currency; reaffirms FY guidance

  GAAP net loss $(20.9)M vs $(53.1)M prior year; adjusted EBITDA $9.7M (4.9% of pro forma sales) vs $11.4M (6.0%) prior year.

• April 9, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 5.02item 9.01 ◈ Earnings Releases ×2

  Orthofix reports prelim Q1 net sales $196.7M, realigns spine leadership, Reinhardt to depart

  Preliminary Q1 net sales $196.7M; reported constant currency +0.4%, pro forma constant currency +2.7% YoY.

• February 24, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Orthofix Q4 net sales $219.9M, net loss narrows; FY26 guidance $850-860M sales, $95-98M adj. EBITDA

  Q4 net loss $(2.2)M vs $(29.1)M YoY; adjusted EBITDA $29.2M (13.4% margin), up 230 bps.

• November 4, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Orthofix Q3 pro forma net sales up 5.7%; adj EBITDA margin expands to 12.1%

  Pro forma net sales $203.4M, +5.7% constant currency vs Q3 2024; reported net sales $205.6M.

• August 5, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Orthofix Q2 net sales $203.1M (+2.3%); adj. EBITDA $20.6M; positive FCF; reaffirms FY25 guide

  Pro forma net sales (ex-M6) $200.7M, +3.5% constant currency; net loss $(14.1)M vs $(33.4)M prior year.

• May 6, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 7.01item 9.01

  Orthofix Q1 net loss $53.1M; lowers FY2025 net sales guidance to $808-816M

  Q1 pro forma net sales $189.2M, up 4.3% constant currency YoY; GAAP net loss $53.1M ($1.35/share) vs $36.0M loss year ago.

• February 25, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Orthofix reports record Q4 net sales of $215.7M (+8% YoY); guides FY25 sales $818-826M, adj. EBITDA $82-86M

  Q4 net sales $215.7M (+8% YoY); record BGT $63.9M (+9%) and Global Orthopedics $35.8M (+18% cc).

• November 8, 2024, 6:59 PM ET debt materiality 0.70 neutral item 1.01item 1.02item 2.03item 9.01

  Orthofix enters $275M secured credit facility with Oxford Finance; repays Blue Torch loan

  New credit agreement provides $160M term loan, $65M delayed draw, and up to $50M discretionary facility, maturing Nov 2029.

• November 7, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Orthofix Q3 net sales $196.6M (+7%), adjusted EBITDA $19.2M, introduces 2027 targets

  Net sales $196.6M, +7% YoY; U.S. Spine Fixation +18%, U.S. Orthopedics record quarter +15%.

• August 6, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Orthofix Q2 net sales $198.6M (+6% YoY); raises FY2024 guidance

  Q2 net sales $198.6M, +6% YoY; net loss $(33.4M) vs $(39.4M) prior year; EPS $(0.88).

• May 7, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Orthofix Q1: net sales $188.6M (+7.7%), net loss narrows to $36M; raises FY sales outlook to $790-795M

  Net sales $188.6M, +7.7% YoY; Bone Growth Therapies +10%, U.S. Spine Fixation +16%, U.S. Orthopedics +23%.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.70 · Most common event earnings

7 positive 2 negative 7 neutral

source · OFIX on sec.gov